"Psoriasis Treatments in Non-White Racial Ethnic Groups"
Andrew Alexis, MD, MPH, director of the Skin of Color Center at Mount Sinai and chair of the department of dermatology at Mount Sinai St. Luke’s and Mount Sinai West, shares some of his his perspectives from both the Skin of Color Society’s recent annual meeting and the American Academy of Dermatology’s recent annual meeting. “I had a couple posters related to psoriasis in specific subpopulations. One paper looked at a topical agent that contains halobetasol and tazarotene as a fixed combination used for four weeks in psoriasis patients. We looked specifically at the Hispanic subgroup of a larger phase III trial and found significant results in terms of investigator global assessment over a four-week period in our Hispanic patient population compared to vehicle.” Dr. Alexis added, “Studies like this are important because there's really a dearth of information about psoriasis treatments in non-white racial ethnic groups, and so with studies like this, we can advance our understanding of any nuances in managing psoriasis across the diverse spectrum of racial ethnic groups and skin types.”
— Andrew Alexis, MD, MPH, Associate Professor, Dermatology, Icahn School of Medicine at Mount Sinai, Director, The Skin of Color Center at Mount Sinai, Site Chair, Department of Dermatology, Mount Sinai St. Luke’s-Mount Sinai West